- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
Selleck製品は、NatureやScience等の権威ある科学雑誌に掲載された論文中で数多く使用されています
16名のノーベル賞受賞者が52報の論文においてセレック製品を使用
David Baker
Won the Nobel Prize in Chemistry in 2024
Michael Houghton
Won the Nobel Prize in Physiology or Medicine in 2020
Charles M. Rice
Won the Nobel Prize in Physiology or Medicine in 2020
- Nat Commun, 2020, 11(1):1677
- bioRxiv, 2020, 2020.10.09.334128
- bioRxiv, 2020, 2020.01.20.910927
- Viruses, 2019, 11(11)E1039
- Cell Rep, 2018, 25(4):833-840.e3
- Cell, 2018, 172(3):423-438.e25
- Gastroenterology, 2017, 153(2):566-578.e5
- Gastroenterology, 2016, 150(1):82-85.e4
- Antimicrob, 2016, 60(6):3786-93
- Nature, 2015, 524(7566):471-5
- Antimicrob, 2015, 59(6):3482-92
- J Virol, 2014, 88(20):12098-111
- Antimicrob, 2014, 58(9):5386-94
- J Virol, 2013, 87(13):7593-607
- Nature, 2013, 501(7466):237-41
- Nature, 2013, 99(1):6-11
- Antimicrob, 2012, 56(10):5365-73
William G. Kaelin Jr
Won the Nobel Prize in Physiology or Medicine in 2019
Peter J. Ratcliffe
Won the Nobel Prize in Physiology or Medicine in 2019
Gregg L. Semenza
Won the Nobel Prize in Physiology or Medicine in 2019
Michael Rosbash
Won the Nobel Prize in Physiology or Medicine in 2017
Shinya Yamanaka
Won the Nobel Prize in Physiology or Medicine in 2012
Eric Richard Kandel
Won the Nobel Prize in Physiology or Medicine in 2000
Aziz Sancar
Won the Nobel Prize in Chemistry in 2015
Brian K. Kobilka
Won the Nobel Prize in Chemistry in 2012
Robert Lefkowitz
Won the Nobel Prize in Chemistry in 2012
化合物ライブラリー
全製品FDA,EMA,HMA,CFDA,PMDAなどの機関から承認済み、またはUSP,BP,EP,JP,Ph.Intなどの薬局方に情報が収載されています。
新製品
G150 is a potent and highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with IC50 of 10.2 nM.
TH5487 is a selective active-site inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 342 nM.
KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 exhibits antidiabetic efficacy in rodent models.
Mizagliflozin is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation.
Guadecitabine (SGI-110) is a next-generation hypomethylating agent whose active metabolite decitabine has a longer in-vivo exposure time than intravenous decitabine.
CM-272 is a novel first-in-class dual reversible inhibitor of G9a (GLP) and DNMTs with IC50 of 8 nM, 382 nM, 85 nM, 1200 nM, 2 nM for G9a, DNMT1, DNMT3A, DNMT3B, GLP, respectively. CM-272 prolongs survival in in vivo models of haematological malignancies by at least in part inducing immunogenic cell death.
INT-777 (S-EMCA) is a novel potent and selective TGR5 agonist with EC50 values of 0.18 μM, 3.9 μM and 1.45 μM for WT TGR5, TGR5(N76A) and TGR5(Y89F) respectively.
BAY 1125976 is a selective allosteric AKT1/2 inhibitor,exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. BAY1125976 inhibits the activity of AKT1 (IC50 = 5.2 nM at 10 µM ATP and 44 nM at 2 mM ATP) and AKT2 (IC50 = 18 nM at 10 µM ATP and 36 nM at 2 mM ATP) very potently.Whereas BAY1125976 is almost inactive on AKT3 (IC50 = 427 nM at 10 µM ATP).
Tags: kinase inhibitors, tyrosine kinase inhibitors, enzyme inhibitors, protein inhibitors, proteins kinase inhibitors, small molecules, phosphatase inhibitors
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間